JacquebecI find getting emails from austin to my queries the best route, because then I have time to absorb them and fine tune the concern, and I also have a record of what was discussed should clarification be needed later.
I also phone, but not that often.
He can be emailed at the biotech direct email address that should follow any newsrelease as a rule, or if you go to the link for biosnapshots, and scroll down, it should be there biotech@direct.ca
I believe is the link off the top my head, but I will double check.
I have bought into bio as a long term play. Because I do believe that once they are solidlity in Mexico and adding to their levels of profitability, once that bench mark is reached, they will with the other countries just continue to ratchet up the numbers.
However Spinner is also correct in that up until now, and likely on going still bio can be played as well as a trading stock, due to its volatility. Also now that it has sales it will have a useful peg ratio so you can calibrate the rate of growth and the pace of growth as it moves towards breakeven and beyond.
The profit margin in this is quite generous. However you will also have to keep in the back of your mind the impact of ALLBURG..75 percent goes to shareholders, but the other 25 percent goes to quess who once we are profitable.
But I understand that the directors have already adjusted some of their mkt costs so that the Allburg impact will kick in later than the recent figures per the tsx,v suggested.
Also there is a return of mkting costs I believe it is, once sales reach a certain level in addition to the clear margin.
As it is I understand that breakeven is at 10,000 units per month. However you would want to average the quarter figures to get that as one month may have a heavy feeder compared to the next, until things get nicely over that break even point. Five Dollars per unit US I think is the money free and clear from each unit sale.
They are also working on the next internet sales version, fine tuning it, and the sales for that may have even a larger margin of profit for bio.
The sales to the poor in Mexico which the govt underwrites do not impact on bio's profit margin.
So what to watch is the momemtum of sales growing. And I understand that they will piggyback the approvals in Mexico and sales and quick step to profitability in Mexico..or this is the hope plus the approval in Peru..to encourage the distribution and subsequent approval for other spots eg Brazil and Argentina. The population targets there are also large, and thus the 'sweet spot' in sales can be reached more quickly and cost effectively going there next rather than to Peru..I am told.
So you should look at some point for the distribution agreement for perhaps Brazil and or Argentina next. And subsequently some several months later, or whenever there will a need for the Health Authority approval to go ahead with sales in those countries. This was what happened for Mexico. Mexico apparently is a conduit to fast forwarding this process in other Latin American countries apparently.
But there is considerable mkt depth to go after in Mexico just alone.
So do email Austin. And also you will get a sense of general timeframe for things, but it usually takes much, much longer when you look at the logistics to get to where they want things to do.
First major hurdle is that tsx halt being lifted and approval of both new directors. However business will continue.
Sedar should have some more information on sales for the OCT to DEc timeframe I believe at the end of FEB or thereabouts..maybe early March as FEB is a short month. This still has to be posted.
Austin has also indicated in past conversations that if a product of this nature is launched successfully, then it usually is still around and kicking 20 years later, looking at similar products from competitors. So the key thing now is watching to see that the product launch does have legs..etc and momentum and will be sustainable.
Once it is solidly in Mexico and heading to other distribution venues, things should be very, very interesting. BUT we have to get there first. It will be interesting to also find out who the new directors will be, and I think this will be a very significant turning point for biotech.